Highlights from

ECCO 2019

European Crohn's and Colitis Organisation's 14th congress

Copenhagen 6-9 March 2019

HDAC6 inhibition by CKD-506

CKD-506 has been found to have therapeutic effects in various colitis animal models. Therefore, this oral selective histone deacetylase 6 (HDAC6) inhibitor may exert beneficial effect in patients with Crohn’s disease and ulcerative colitis. The effect of CKD-506 on rheumatoid arthritis is already being evaluated in a clinical phase 2 study.

In the preclinical study presented at ECCO 2019, HDAC6 was overexpressed in colon tissue of patients with Crohn’s disease and ulcerative colitis [1]. In vitro, HDAC6 overexpression by plasmid DNA strongly induced the production of various inflammatory mediators, especially TNFα, IL-6, IP-10, and ROS production from macrophages. However, CKD-506 inhibited HDAC6-mediated inflammatory responses in macrophages through NF-κB and AP-1. In vivo, CKD-506 strongly inhibited disease activity indexes in DSS-, TNBS-, piroxicam- (IL-10−/−)-, and adaptive T cell transfer-mediated colitis. In acute colitis models, CKD-506 inhibited IL-6 and TNFα expression in colon tissue of DSS-induced colitis; it also inhibited ICAM-1, VCAM-1, and IP-10 expression in colon tissue of a TNBS-induced colitis model. In addition, CKD-506 inhibited IκB phosphorylation, IL-6, and TNFα expression in colon tissue and mononuclear cells of lamina propria in piroxicam-induced colitis of IL-10−/− mice. Moreover, CKD-506 inhibited various inflammatory cytokines in serum as well as in colon tissue of T cell adaptive transfer colitis of RAG−/− mice.

Keywords: Crohn’s disease, ulcerative colitis, inflammation, interleukin

  1. Shin J, et al. ECCO 2019, OP23.

The content and interpretation of these conference highlights are the views and comments of the speakers/authors.